Lymphoma Clinical Trials in Tennessee

Showing 541-560 of 563 trials

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

NCT00193505

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

Non-Hodgkins Lymphoma

SCRI Development Innovations, LLC40 participantsStarted Oct 2003

Nashville, Tennessee, United States

COMPLETEDPhase 129 miles

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

NCT00470405

RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with oxaliplatin may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed given together with oxaliplatin in treating patients with metastatic solid tumors or lymphoma.

LymphomaSolid Tumor

Vanderbilt-Ingram Cancer Center25 participantsStarted May 2004

Nashville, Tennessee, United States

COMPLETEDPhase 229 miles

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Mantle Cell Lymphoma

Millennium Pharmaceuticals, Inc.152 participantsStarted Jun 2003

Birmingham, Alabama, United States • Berkeley, California, United States • Duarte, California, United States +32 more locations

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Other Conditions in Tennessee